These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 23830577)

  • 21. Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.
    Li Q; Alsaidan OA; Ma Y; Kim S; Liu J; Albers T; Liu K; Beharry Z; Zhao S; Wang F; Lebedyeva I; Cai H
    J Biol Chem; 2018 Apr; 293(17):6434-6448. PubMed ID: 29540482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of FGFs/FGFRs in skeletal development and bone regeneration.
    Du X; Xie Y; Xian CJ; Chen L
    J Cell Physiol; 2012 Dec; 227(12):3731-43. PubMed ID: 22378383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct FGF receptor 1 activation through an anti-idiotypic strategy mimicks the biological activity of FGF-2 and inhibits the progression of the bladder carcinoma derived from NBT-II cells.
    Malavaud B; Pedron S; Sordello S; Mazerolles C; Billottet C; Thiery JP; Jouanneau J; Plouët J
    Oncogene; 2004 Sep; 23(40):6769-78. PubMed ID: 15273729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Approaches targeting the FGF-FGFR system: a review of the recent patent literature and associated advanced therapeutic agents.
    Herbert C; Lassalle G; Alcouffe C; Bono F
    Pharm Pat Anal; 2014; 3(6):585-612. PubMed ID: 25489913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
    Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
    Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
    Hierro C; Rodon J; Tabernero J
    Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice.
    Arbeit JM; Olson DC; Hanahan D
    Oncogene; 1996 Nov; 13(9):1847-57. PubMed ID: 8934530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent developments and advances of FGFR as a potential target in cancer.
    Xue WJ; Li MT; Chen L; Sun LP; Li YY
    Future Med Chem; 2018 Sep; 10(17):2109-2126. PubMed ID: 30066580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
    Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Development and ligand-protein interaction of small molecule anti-tumor FGFR inhibitors].
    Li XL; Qiu R; Li J; Hai L; Wu Y
    Yao Xue Xue Bao; 2016 Nov; 51(11):1689-97. PubMed ID: 29908111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isoforms of receptors of fibroblast growth factors.
    Gong SG
    J Cell Physiol; 2014 Dec; 229(12):1887-95. PubMed ID: 24733629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
    Repetto M; Crimini E; Giugliano F; Morganti S; Belli C; Curigliano G
    Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1233-1252. PubMed ID: 34591728
    [No Abstract]   [Full Text] [Related]  

  • 33. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
    Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
    J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach.
    Presta M; Chiodelli P; Giacomini A; Rusnati M; Ronca R
    Pharmacol Ther; 2017 Nov; 179():171-187. PubMed ID: 28564583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis.
    Dey JH; Bianchi F; Voshol J; Bonenfant D; Oakeley EJ; Hynes NE
    Cancer Res; 2010 May; 70(10):4151-62. PubMed ID: 20460524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling.
    Agrawal S; Maity S; AlRaawi Z; Al-Ameer M; Kumar TKS
    Curr Drug Targets; 2021; 22(2):214-240. PubMed ID: 33045958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway.
    Lee PS; Secord AA
    Cancer Treat Rev; 2014 May; 40(4):507-12. PubMed ID: 24332498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The roles of the FGF signal in zebrafish embryos analyzed using constitutive activation and dominant-negative suppression of different FGF receptors.
    Ota S; Tonou-Fujimori N; Yamasu K
    Mech Dev; 2009; 126(1-2):1-17. PubMed ID: 19015027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
    Byron SA; Loch DC; Pollock PM
    Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FGFR-targeted therapeutics for the treatment of breast cancer.
    De Luca A; Frezzetti D; Gallo M; Normanno N
    Expert Opin Investig Drugs; 2017 Mar; 26(3):303-311. PubMed ID: 28121208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.